Navigation Links
PCMA on IOM Essential Health Benefits Report: Employers and Special Interests Will Spar Over Costly Prescription Drug Mandates
Date:10/7/2011

WASHINGTON, Oct. 7, 2011 /PRNewswire-USNewswire/ -- By urging the U.S. Department of Health and Human Services (HHS) to issue "Essential Health Benefits" regulations that ensure affordable, flexible benefits in the exchanges, the Institute of Medicine (IOM) has launched a long-overdue debate between employers and some powerful special interests that benefit from costly new mandates, according to the Pharmaceutical Care Management Association (PCMA).

A new survey shows that small employers strongly oppose many of the regulations that special interests routinely ask HHS to impose on plans that offer drug coverage.  These include restrictions on mail-service pharmacy, drugstore networks, generic drugs, pricing models, and overall benefit design.

"On prescription drug issues, employers want access to affordable plans that promote mail-service pharmacy, offer less expensive drugstore networks, and don't require small businesses to bear the full cost of drugs that can cost $100,000 or more.  Some powerful special interests, however, profit from mandates that prohibit plans from offering these options in the exchanges," said PCMA President and CEO Mark Merritt.

Small businesses will be among those most affected by the Essential Health Benefit rules, which apply to employers that purchase coverage and have fewer than one hundred employees, as well as qualified health plans in the state exchanges.  Pharmacy benefit managers (PBMs) administer drug benefits for thousands of small businesses throughout America.

The survey of owners and human resource managers of small businesses with 100 or fewer employees directly impacted by the upcoming Essential Health Benefits regulations found that by a 78 to 11 percent margin, "small businesses should be able to reduce prescription drug costs as much as possible, even if it means drugstores make less profit." Only six per
'/>"/>

SOURCE Pharmaceutical Care Management Association
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Nationwide Survey Reports that Mothers View Cleaning Homes and Toys as Essential to Preventing Colds & Flu
2. Precise Low-Dose Drug Monitoring Essential for Long-Term Kidney Transplant Success
3. Essentialis Completes Patient Enrollment in Phase 2 Trial of DDCR for Treatment of Dyslipidemia
4. Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatment of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US
5. Essentialis to Submit SPA for Hypertriglyceridemia
6. Weekly Digests Investor Essentials Special Report Identifies Unique Investing Opportunities in the H1N1 Swine Flu Outbreak
7. Creative Alliances with Nontraditional Players Increasingly Essential for Survival in Pharmaceutical Industry, New Ernst & Young Report Finds
8. Health Outcomes Data Essential to Biopharmaceutical Sales Process
9. Laerdal Introduces SimMan Essential
10. Essentialis Strengthens Patent Protection of Its Novel ATP-Sensitive Potassium Channel Opener Portfolio
11. Essential Pharmaceuticals Acquires Exclusive Worldwide Rights to Family of Cell Media Products from Lifeblood Medical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , March 2, 2015 Isis Pharmaceuticals, Inc. (NASDAQ: ... a $15 million milestone payment from GSK related to advancing ... with familial amyloid polyneuropathy (FAP).  "We are ... Rx , and plan to report data from the Phase ... the fifteen months of dosing and are now receiving ISIS-TTR ...
(Date:3/2/2015)... N.J. and BETHESDA, Md. ... development-stage immunotherapy company focused on treating and preventing autoimmune ... 2-stage, anti-IL-15 monoclonal antibody (AMG 714) from Amgen (NASDAQ: ... exclusive license agreement, Celimmune has the rights to develop, ... excluding Japan . Concurrently, Amgen has ...
(Date:3/2/2015)... Texas , March 2, 2015   Lexicon ... biopharmaceutical company focused on developing breakthrough treatments for human ... 2014 financial results on Wednesday, March 4, 2015 before ... conference call and webcast to discuss clinical development progress ... end of 2014 at 10:00 a.m. Eastern Time on ...
Breaking Medicine Technology:Isis Pharmaceuticals Earns $15 Million From GSK for Advancing ISIS-TTR Rx 2Isis Pharmaceuticals Earns $15 Million From GSK for Advancing ISIS-TTR Rx 3Celimmune Announces Anti-IL-15 Antibody Licensing and Option Agreements with Amgen 2Celimmune Announces Anti-IL-15 Antibody Licensing and Option Agreements with Amgen 3Lexicon To Report Fourth Quarter And Year End 2014 Financial Results On March 4, 2015 2
... Inc. (Nasdaq: STXS ) announced today that the underwriters ... have exercised in full their over-allotment option to purchase an ... 7,475,000 shares of Stereotaxis common stock in the offering, including ... sold at a price to the public of $4.00 per ...
... 12 Leaders of the medical technology industry ... E. Washington Convention Center for the third annual ... mix of medical technology executives, innovators, policymakers, media, ... and 32 states, are expected to attend this ...
Cached Medicine Technology:Stereotaxis Announces Underwriters' Exercise of Over-Allotment Option 2Stereotaxis Announces Underwriters' Exercise of Over-Allotment Option 3Medical Technology Executives Descend on D.C. as AdvaMed 2009: The MedTech Conference Kicks Off and Health Care Debate Continues 2Medical Technology Executives Descend on D.C. as AdvaMed 2009: The MedTech Conference Kicks Off and Health Care Debate Continues 3
(Date:3/2/2015)... 2015 Representatives with BNatrl ( ... launched a multivitamin supplement that’s specifically designed for ... for BNatrl, said the multivitamin, which launched Jan. ... other world-class athletes. , "Being an avid marathon ... whole food multivitamin to improve my performance,” said ...
(Date:3/2/2015)... Atlantic Information Services, Inc. (AIS) is pleased to ... Plans: 2015 , the all-new 12th edition of the ... market, with enrollment data and contact information for health ... as a printed book containing the full directory and ... and charts, as well as an electronic version, AIS’s ...
(Date:3/2/2015)... TX (PRWEB) March 02, 2015 What ... How should physicians request references? When are interviews scheduled, ... analyze employment opportunities?, Both training and practicing physicians who ... to these questions and more at the PracticeLink Physician ... 18. The drop-in Job Fair is from 5:30 to ...
(Date:3/2/2015)... Final Cut Pro X plugin specialists have ... Film Studios. , “The TranStatic Volume 2 plugin gives users ... CEO of Pixel Film Studios. “TranStatic Volume 2 is a ... editors toolbox.” , With TranStatic Volume 2 users can transition ... scrambling effects from Pixel Film Studios. Users have total control ...
(Date:3/1/2015)... Excellence is pleased to announce the addition of a digital ... are over 75 terms and phrases available for viewing, with more ... patients a better understanding of what our Providers are talking about ... With this resource, our patients are able to go back to ... that they may not remember or comprehend at the time of ...
Breaking Medicine News(10 mins):Health News:Bnatrl Launches Multivitamin Supplement for Runners 2Health News:Now Available from AIS: 12th Edition of Annual Book Containing Health Plan Enrollment Data, Contact Information 2Health News:PracticeLink to Host a Career Advancement Workshop and Job Fair in Houston 2Health News:Pixel Film Studios released the TranStatic Volume 2 plugin for Final Cut Pro X today 2
... of brain tumor , , MONDAY, June 2 (HealthDay News) -- ... malignant brain tumor that was diagnosed last month. , The ... an especially lethal type of brain tumor, at Duke University ... Massachusetts Democrat,s office said he would be operated on by ...
... in 81 years the International Congress of Genetics takes place ... Nobel Prize winners get together with more than 2000 scientists ... genome analysis. The congress, which takes place for the 20th ... also being Berlin. Congress Chairman is Prof. Rudi Balling, Scientific ...
... PETERSBURG, Fla., June 2 The Advanced,Wound Management Division ... that its negative pressure wound therapy (NPWT) products will ... included in the,first phase of the competitive bidding program ... in the U.S. The program, which is,scheduled to take ...
... completed ... phase I studies, SAN ... of a worldwide exclusive agreement entered into in Feb,2008, GlaxoSmithKline (GSK) ... original agreement, GSK has rights to develop,manufacture and commercialize FLAP (5-Lipoxygenase ...
... Imagine being able to communicate,your practice,s message to ... practice growth and development. That is the focus of ... parent company of JG Pads, a pharmaceutical sales,support company ... United States since 1993. Because of its success, MarketHATCH ...
... Scientists at the University of Liverpool have found that ... antibiotics, suggesting that the infection is unlike the bacteria ... resistant to antibiotics and can sometimes go undetected in ... spread to humans. The team tested the strains found ...
Cached Medicine News:Health News:Sen. Kennedy Undergoing Surgery for Brain Tumor 2Health News:Sen. Kennedy Undergoing Surgery for Brain Tumor 3Health News:Sen. Kennedy Undergoing Surgery for Brain Tumor 4Health News:6 Nobel Prize Winners at International Congress of Genetics 2Health News:6 Nobel Prize Winners at International Congress of Genetics 3Health News:Smith & Nephew Negative Pressure Wound Therapy Products To Be Available To Patients Through the Medicare Part B Competitive Bidding Process 2Health News:Smith & Nephew Negative Pressure Wound Therapy Products To Be Available To Patients Through the Medicare Part B Competitive Bidding Process 3Health News:Smith & Nephew Negative Pressure Wound Therapy Products To Be Available To Patients Through the Medicare Part B Competitive Bidding Process 4Health News:Smith & Nephew Negative Pressure Wound Therapy Products To Be Available To Patients Through the Medicare Part B Competitive Bidding Process 5Health News:Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline 2Health News:Ohio Company to Debut Turnkey Marketing Material During Florida National Dental Convention 2Health News:Salmonella in garden birds responsive to antibiotics 2
Take Performance to a Higher Level....
The MULTI-LINK PIXEL Coronary Stent System was designed to address the challenges of small vessel treatment in patients with abrupt or threatened abrupt closure (ATC)....
FemoStop plus system is a femoral compression system for hemostasis management. It provides a comfortable and efficient "hands off method of compressing the femoral artery and vein after diagnostic ...
... used to seal the arterial puncture site. Duett ... the arteriotomy and the tissue tract with a ... a balloon catheter and procoagulant - the Duett ... stop the bleeding. The Duett is unique in ...
Medicine Products: